Related Experiment Video
Updated: Jul 1, 2025
An Ex Vivo Brain Slice Model to Study and Target Breast Cancer Brain Metastatic Tumor Growth
Published on: September 22, 2021
Relationship between the Expression of Matrix Metalloproteinases and Their Tissue Inhibitors in Patients with Brain
Katarina Dibdiakova1,2, Zuzana Majercikova1, Tomas Galanda3
1Department of Medical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Mala Hora 11161/4D, 03601 Martin, Slovakia.
Abstract:
Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) play critical roles in regulating processes associated with malignant behavior. These endopeptidases selectively degrade components of the extracellular matrix (ECM), growth factors, and their receptors, contributing to cancer cell invasiveness and migratory characteristics by disrupting the basal membrane. However, the expression profile and role of various matrix metalloproteinases remain unclear, and only a few studies have focused on differences between diagnoses of brain tumors. Using quantitative real-time PCR analysis, we identified the expression pattern of ECM modulators (n = 10) in biopsies from glioblastoma (GBM; n = 20), astrocytoma (AST; n = 9), and meningioma (MNG; n = 19) patients. We found eight deregulated genes in the glioblastoma group compared to the benign meningioma group, with only MMP9 (FC = 2.55; p = 0.09) and TIMP4 (7.28; p < 0.0001) upregulated in an aggressive form. The most substantial positive change in fold regulation for all tumors was detected in matrix metalloproteinase 2 (MNG = 30.9, AST = 4.28, and GBM = 4.12). Notably, we observed an influence of TIMP1, demonstrating a positive correlation with MMP8, MMP9, and MMP10 in tumor samples. Subsequently, we examined the protein levels of the investigated MMPs (n = 7) and TIMPs (n = 3) via immunodetection. We confirmed elevated levels of MMPs and TIMPs in GBM patients compared to meningiomas and astrocytomas. Even when correlating glioblastomas versus astrocytomas, we showed a significantly increased level of MMP1, MMP3, MMP13, and TIMP1. The identified metalloproteases may play a key role in the process of gliomagenesis and may represent potential targets for personalized therapy. However, as we have not confirmed the relationship between mRNA expression and protein levels in individual samples, it is therefore natural that the regulation of metalloproteases will be subject to several factors.
Insights
Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are key in brain tumor progression. This study reveals their altered expression in glioblastoma, suggesting potential therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are crucial regulators of extracellular matrix remodeling, influencing cancer cell behavior.
- Their specific roles and expression patterns in different brain tumor types, particularly in distinguishing aggressive from benign forms, remain incompletely understood.
Purpose of the Study:
- To investigate the differential expression profiles of selected matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in various brain tumors, including glioblastoma, astrocytoma, and meningioma.
- To correlate gene expression with protein levels and identify potential molecular markers for gliomagenesis and therapeutic targets.
Main Methods:
- Quantitative real-time PCR was employed to analyze the mRNA expression of 10 ECM modulators in tumor biopsies from glioblastoma (n=20), astrocytoma (n=9), and meningioma (n=19) patients.
- Immunodetection was used to assess the protein levels of 7 MMPs and 3 TIMPs.
- Statistical analysis was performed to compare expression levels between tumor types and identify correlations.
Main Results:
- Eight genes were found to be deregulated in glioblastoma compared to meningioma. MMP9 and TIMP4 were upregulated in aggressive glioblastoma.
- Matrix metalloproteinase 2 (MMP2) showed the highest fold regulation across all tumor types. TIMP1 positively correlated with MMP8, MMP9, and MMP10 expression.
- Elevated protein levels of MMPs and TIMPs were confirmed in glioblastoma patients compared to meningiomas and astrocytomas. Glioblastomas showed significantly higher levels of MMP1, MMP3, MMP13, and TIMP1 compared to astrocytomas.
Conclusions:
- The identified matrix metalloproteinases and tissue inhibitors of metalloproteinases play significant roles in gliomagenesis.
- These molecules represent potential targets for developing personalized therapies for brain tumors.
- Further investigation is needed to confirm the relationship between mRNA and protein expression in individual samples and to elucidate the complex regulatory mechanisms.
Related Concept Videos
02:17The Tumor Microenvironment
01:23Role of Matrix Metalloproteases in Degradation of ECM